Propylthiouracil-induced lupus, antiphospholipid syndrome, and stroke in a patient with graves hyperthyroidism

Archives of Neurology

Volumn 68, Issue 12, 2011, Pages 1587-1590

  Ortiz, Gustavo A ^a   Lagari Libhaber, Violet ^a   Prieto Sanchez, Luz Marina ^a   Rabinstein, Alejandro A ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; LUPUS ANTICOAGULANT; METOPROLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; SJOEGREN ANTIBODY; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN ISCHEMIA; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERCOAGULABILITY; LUPUS LIKE SYNDROME; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROTOXICOSIS;

EID: 83455217477     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.838     Document Type: Article

References (14)

1. Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005;36(10):2302-2310. (Pubitemid 41429267)
2. Verberne HJ, Fliers E, Prummel MF, Stam J, Brandjes DP, Wiersinga WM. Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis. Thyroid. 2000;10(7):607-610. (Pubitemid 30670622)
3. Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves disease: special considerations regarding clinical significance and management. J Neurosurg. 2005;102(6):1013-1017.
4. Davies TF. Propylthiouracil in Graves' disease. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia, PA: Saunders; 2003:393-395.
5. Hess E. Drug-related lupus. N Engl J Med. 1988;318(22):1460-1462.
6. Prasad GV, Bastacky S, Johnson JP. Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. J Am Soc Nephrol. 1997;8(7):1205-1210.
7. Yamada A, Sato K, Hara M, et al. Propylthiouracil-induced lupus-like syndrome developing in a Graves' patient with a sibling with systemic lupus erythematosus. Intern Med. 2002;41(12):1204-1208. (Pubitemid 36150028)
8. Ligier S, Pham CD, Watters AK, Kassis J, Fortin PR. Purpura fulminans and anticardiolipin antibodies in a patient with Grave's disease. Scand J Rheumatol. 2002;31(6):371-373. (Pubitemid 35398748)
9. Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum. 2006;36(1):4-9. (Pubitemid 44144499)
10. Cervera R, Piette JC, Font J, et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4): 1019-1027. (Pubitemid 34303815)
11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
12. Hahn BH. Systemic lupus erythematosus. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Professional; 2008:2083.
13. Sánchez-Guerrero J, Lew RA, Fossel AH, Schur PH. Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996;39(6):1055-1061. (Pubitemid 26182077)
14. Wu R, Li R. Propylthiouracil-induced autoimmune syndromes: 11 case report [published online December 7, 2010]. Rheumatol Int. doi:10.1007/s00296-010- 1675-z.